Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Aesomed Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Aesomed Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aesomed Bioscience
Developer of recombinant exosome biotechnology designed to advance regenerative medicine and anti-ageing therapeutics. The company offers patented AesoBoost technology, achieving high-yield, high-purity exosome production with precise quality control, enabling biopharmaceutical, medical aesthetics, and skincare industries to achieve safer, scalable, and clinically validated biotechnological applications.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Aesomed Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aesomed Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aesomed Bioscience in its N-PORT filings yet. We sweep new filings monthly.